, /PRNewswire/ -- GRAIL, Inc. (Nasdaq: ), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first participant has been enrolled in the REACH/Galleri-Medicare study at Community Health Network, a leading integrated healthcare system in central with more than 200 sites of care. With age being the most significant risk factor for cancer, Medicare beneficiaries face a critical unmet need for early cancer detection.
"We are excited about the REACH study and the work that GRAIL is doing to detect cancer early when it is more likely to be successfully treated," said , M.D., Executive Vice President, Chief Transformation Officer and Principal Investigator of the REACH study at Community Health Network.
"As a health network committed to exceptional care for patients, it was important for Community Health Network to participate in the REACH study. We really want to expand upon and understand the real-world evidence of the Galleri test. Since the focus is on underrepresented minorities, we felt strongly that this was an opportunity to offer the test as part of the REACH study to many of the people who are traditionally or historically underrepresented in clinical studies.
We feel strongly about the science of the test and the potential it holds to improve health outcomes for our Medicare patients." The eal-world vidence to dvance Multi- ancer Early Detection ealth Equity (REACH/Galleri-Medicare) study is a first-of-its-kind real-.
